<DOC>
	<DOCNO>NCT02430922</DOCNO>
	<brief_summary>The objective clinical investigation evaluate short-term ( 12 month ) outcome treatment mean self-expanding iVolution nitinol stent symptomatic ( Rutherford 2-4 ) femoropopliteal arterial stenotic occlusive lesion .</brief_summary>
	<brief_title>Physician-inititated Trial Investigating iVolution Nitinol Stent</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>1 . De novo lesion locate femoropopliteal artery suitable endovascular treatment 2 . Patient present score 2 4 accord Rutherford classification 3 . Patient willing able comply specify followup evaluation predefined time interval 4 . Patient &gt; 18 year old 5 . Patient understands nature procedure provide write informed consent , prior enrollment study 6 . Prior enrollment , target lesion cross standard guidewire manipulation One target lesion locate within native SFA : distal point 3 cm knee joint 7 . The target lesion angiographic evidence stenosis occlusion 8 . Length target lesion ≤ 15 cm visual estimation 9 . Target vessel diameter visually estimate ≥4 mm ≤7 mm 10 . There angiographic evidence least one vesselrunoff foot 1 . Presence stent target vessel place previous procedure 2 . Presence aortic thrombosis significant common femoral ipsilateral stenosis 3 . Previous bypass surgery limb 4 . Patients contraindicate antiplatelet therapy , anticoagulant thrombolytic 5 . Patients exhibit persistent acute intraluminal thrombus target lesion site 6 . Perforation angioplasty site evidence extravasation contrast medium 7 . Patients know hypersensitivity nickeltitanium study device component 8 . Patients uncorrected bleed disorder 9 . Female patient child bear potential take adequate contraceptive currently breastfeed 10 . Life expectancy le 12 month 11 . Ipsilateral iliac artery treatment target lesion treatment residual stenosis &gt; 30 % 12 . Use thrombectomy , atherectomy laser device procedure 13 . Any patient consider hemodynamically unstable onset procedure 14 . Patient currently participate another investigational drug device study reach primary endpoint</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>